Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.
TAR-200 and nadofaragene firadenovec achieved sustained complete responses in bladder cancer patients who had failed prior BCG therapy.
This randomized controlled trial examined Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS. Restricted mean survival time (RMST) for DoR was estimated at 6, 12, 18, and 24 months.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants or patients described in the PubMed abstract
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Anticancer research
Why it surfaced
Randomized controlled trial; conservative rapid-triage score based on novelty, clinical relevance, design quality, and population or unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.